These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 18831725)

  • 1. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 2. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
    Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
    J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
    Hugh J; Barley R; Dabbagh L
    Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
    [No Abstract]   [Full Text] [Related]  

  • 8. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
    Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
    Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR; Stoler MH
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prognostic factors of breast cancer].
    Tang P; Wei B; Yang WJ; Liu YS; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799
    [No Abstract]   [Full Text] [Related]  

  • 14. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER; Tubbs RR; Myles JL; Procop GW
    Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
    Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
    Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.